New York State Common Retirement Fund’s Ascendis Pharma A/S ASND Stock Holding History

New York State Common Retirement Fund’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.2M	Buy	191,791 +20,679	+12%	+$4.83M	0.06%	213
2026 Q1	$39.1M	Sell	171,112 -11,122	-6%	-$2.49M	0.05%	250
2025 Q4	$38.9M	Buy	182,234 +12,340	+7%	+$2.55M	0.05%	243
2025 Q3	$33.8M	Sell	169,894 -12,664	-7%	-$2.36M	0.04%	291
2025 Q2	$31.5M	Sell	182,558 -21,924	-11%	-$3.57M	0.04%	296
2025 Q1	$31.9M	Hold	204,482	–	–	0.05%	286
2024 Q4	$28.2M	Buy	204,482 +25,164	+14%	+$3.31M	0.04%	337
2024 Q3	$26.8M	Sell	179,318 -20,083	-10%	-$2.71M	0.04%	369
2024 Q2	$27.2M	Buy	199,401 +3,322	+2%	+$452K	0.04%	389
2024 Q1	$29.6M	Sell	196,079 -8,469	-4%	-$1.21M	0.04%	378
2023 Q4	$25.8M	Sell	204,548 -152	-0.1%	-$15.2K	0.04%	420
2023 Q3	$19.2M	Sell	204,700 -3	-0%	-$281	0.03%	518
2023 Q2	$18.3M	Sell	204,703 -43,818	-18%	-$3.81M	0.02%	606
2023 Q1	$26.6M	Sell	248,521 -6,985	-3%	-$799K	0.04%	454
2022 Q4	$31.2M	Sell	255,506 -22,611	-8%	-$2.63M	0.04%	377
2022 Q3	$28.7M	Buy	278,117 +4,919	+2%	+$466K	0.04%	388
2022 Q2	$25.4M	Sell	273,198 -23,625	-8%	-$2.23M	0.03%	450
2022 Q1	$34.8M	Buy	296,823 +10,291	+4%	+$1.19M	0.04%	414
2021 Q4	$38.5M	Sell	286,532 -46,597	-14%	-$6.93M	0.04%	399
2021 Q3	$53.1M	Buy	333,129 +48,461	+17%	+$6.63M	0.06%	305
2021 Q2	$37.4M	Buy	284,668 +8,291	+3%	+$1.1M	0.04%	415
2021 Q1	$35.6M	Buy	276,377 +5,535	+2%	+$841K	0.04%	419
2020 Q4	$45.2M	Sell	270,842 -16,824	-6%	-$2.78M	0.05%	348
2020 Q3	$44.4M	Buy	287,666 +33,511	+13%	+$4.82M	0.05%	317
2020 Q2	$37.6M	Sell	254,155 -18,829	-7%	-$2.59M	0.05%	350
2020 Q1	$30.7M	Buy	272,984 +15,901	+6%	+$2.07M	0.05%	358
2019 Q4	$35.8M	Sell	257,083 -7,200	-3%	-$800K	0.04%	404
2019 Q3	$25.5M	Sell	264,283 -2,365	-0.9%	-$264K	0.03%	535
2019 Q2	$30.7M	Buy	266,648 +33,600	+14%	+$4.02M	0.04%	462
2019 Q1	$27.4M	Sell	233,048 -1	-0%	-$88	0.04%	502
2018 Q4	$14.6M	Buy	233,049 +71,656	+44%	+$4.5M	0.02%	722
2018 Q3	$11.4M	Buy	161,393 +40,702	+34%	+$2.8M	0.01%	939
2018 Q2	$8.03M	Buy	120,691 +17,852	+17%	+$1.17M	0.01%	1096
2018 Q1	$6.73M	Buy	+102,839	New	+$5.78M	0.01%	1119

Other funds holding ASND

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return

SAM

Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund's ASND Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Ascendis Pharma A/S (ASND) stake by 12% in Q2 2026, buying an estimated $4.83M and bringing the position to 191,791 shares worth $51.2M. The position accounts for 0.06% of the portfolio, ranked #213.

New York State Common Retirement Fund first reported a position in ASND in Q1 2018 and has held it in 34 quarters since. The position peaked at $53.1M in Q3 2021. 67 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

New York State Common Retirement Fund held 191,791 shares of Ascendis Pharma A/S worth $51.2M as of Q2 2026.
New York State Common Retirement Fund bought 20,679 Ascendis Pharma A/S shares in Q2 2026, an estimated $4.83M.
Ascendis Pharma A/S made up 0.06% of New York State Common Retirement Fund's portfolio in Q2 2026, its #213 holding.
New York State Common Retirement Fund first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 34 quarters since.
New York State Common Retirement Fund's Ascendis Pharma A/S position peaked at $53.1M in Q3 2021.
67 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.